Eligard 22

DRUG4 trials

Sponsors

Friedrich-Schiller-Universitaet Jena, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Universitair Medisch Centrum Groningen, Institut Mutualiste Montsouris, Institut Mutualiste Montsouris

Conditions

Intermediate risk prostate cancerPatients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastaseslow-volume metastatic castration-sensitive prostate cancerprostate cancer

Phase 2

EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer: the ENHANCE prospective feasibility trial

RecruitingCTIS2024-518680-36-00

Institut Mutualiste Montsouris, Institut Mutualiste MontsourisIntermediate risk prostate cancer

Start: 2023-03-07Target: 20Updated: 2024-10-25

Phase 3

A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)

Active, not recruitingCTIS2022-502634-52-00

Friedrich-Schiller-Universitaet Jenaprostate cancer

Start: 2023-05-16Target: 280Updated: 2025-08-25

Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial

RecruitingCTIS2023-506698-36-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)low-volume metastatic castration-sensitive prostate cancer

Start: 2024-02-02Target: 400Updated: 2025-12-03

ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

Not yet recruitingCTIS2024-511252-41-00

Universitair Medisch Centrum GroningenPatients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

Target: 280Updated: 2024-07-29